Literature DB >> 30726924

Cystathionine as a marker for 1p/19q codeleted gliomas by in vivo magnetic resonance spectroscopy.

Francesca Branzoli1,2, Clément Pontoizeau3, Lucien Tchara3, Anna Luisa Di Stefano4,5, Aurélie Kamoun6, Dinesh K Deelchand7, Romain Valabrègue1,2, Stéphane Lehéricy1,2, Marc Sanson2,4,8, Chris Ottolenghi3, Małgorzata Marjańska7.   

Abstract

BACKGROUND: Codeletion of chromosome arms 1p and 19q (1p/19q codeletion) highly benefits diagnosis and prognosis in gliomas. In this study, we investigated the effect of 1p/19q codeletion on cancer cell metabolism and evaluated possible metabolic targets for tailored therapies.
METHODS: We combined in vivo 1H (proton) magnetic resonance spectroscopy (MRS) measurements in human gliomas with the analysis of a series of standard amino acids by liquid chromatography-mass spectroscopy (LC-MS) in human glioma biopsies. Sixty-five subjects with low-grade glioma were included in the study: 31 underwent the MRI/MRS examination, 47 brain tumor tissue samples were analyzed with LC-MS, and 33 samples were analyzed for gene expression with quantitative PCR. Additionally, we performed metabolic tracer experiments in cell models with 1p deletion.
RESULTS: We report the first in vivo detection of cystathionine by MRS in 1p/19q codeleted gliomas. Selective accumulation of cystathionine was observed in codeleted gliomas in vivo, in brain tissue samples, as well as in cells harboring heterozygous deletions for serine- and cystathionine-pathway genes located on 1p: phosphoglycerate dehydrogenase (PHGDH) and cystathionine gamma-lyase (CTH). Quantitative PCR analyses showed 40-50% lower expression of both PHGDH and CTH in 1p/19q codeleted gliomas compared with their non-codeleted counterparts.
CONCLUSIONS: Our results provide strong evidence of a selective vulnerability of codeleted gliomas to serine and glutathione depletion and point to cystathionine as a possible noninvasive marker of treatment response.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  1p/19q codeletion; MEGA-PRESS; MRS; brain glioma; cystathionine

Mesh:

Substances:

Year:  2019        PMID: 30726924      PMCID: PMC6556848          DOI: 10.1093/neuonc/noz031

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  39 in total

1.  Modulating the therapeutic response of tumours to dietary serine and glycine starvation.

Authors:  Oliver D K Maddocks; Dimitris Athineos; Eric C Cheung; Pearl Lee; Tong Zhang; Niels J F van den Broek; Gillian M Mackay; Christiaan F Labuschagne; David Gay; Flore Kruiswijk; Julianna Blagih; David F Vincent; Kirsteen J Campbell; Fatih Ceteci; Owen J Sansom; Karen Blyth; Karen H Vousden
Journal:  Nature       Date:  2017-04-19       Impact factor: 49.962

2.  Glutathione and thioredoxin antioxidant pathways synergize to drive cancer initiation and progression.

Authors:  Isaac S Harris; Aislinn E Treloar; Satoshi Inoue; Masato Sasaki; Chiara Gorrini; Kim Chung Lee; Ka Yi Yung; Dirk Brenner; Christiane B Knobbe-Thomsen; Maureen A Cox; Andrew Elia; Thorsten Berger; David W Cescon; Adewunmi Adeoye; Anne Brüstle; Sam D Molyneux; Jacqueline M Mason; Wanda Y Li; Kazuo Yamamoto; Andrew Wakeham; Hal K Berman; Rama Khokha; Susan J Done; Terrance J Kavanagh; Ching-Wan Lam; Tak W Mak
Journal:  Cancer Cell       Date:  2015-01-22       Impact factor: 31.743

3.  Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia.

Authors:  Christian M Metallo; Paulo A Gameiro; Eric L Bell; Katherine R Mattaini; Juanjuan Yang; Karsten Hiller; Christopher M Jewell; Zachary R Johnson; Darrell J Irvine; Leonard Guarente; Joanne K Kelleher; Matthew G Vander Heiden; Othon Iliopoulos; Gregory Stephanopoulos
Journal:  Nature       Date:  2011-11-20       Impact factor: 49.962

4.  Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.

Authors:  Changho Choi; Jack M Raisanen; Sandeep K Ganji; Song Zhang; Sarah S McNeil; Zhongxu An; Akshay Madan; Kimmo J Hatanpaa; Vamsidhara Vemireddy; Christie A Sheppard; Dwight Oliver; Keith M Hulsey; Vivek Tiwari; Tomoyuki Mashimo; James Battiste; Samuel Barnett; Christopher J Madden; Toral R Patel; Edward Pan; Craig R Malloy; Bruce E Mickey; Robert M Bachoo; Elizabeth A Maher
Journal:  J Clin Oncol       Date:  2016-10-31       Impact factor: 44.544

5.  Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy.

Authors:  Ovidiu C Andronesi; Grace S Kim; Elizabeth Gerstner; Tracy Batchelor; Aria A Tzika; Valeria R Fantin; Matthew G Vander Heiden; A Gregory Sorensen
Journal:  Sci Transl Med       Date:  2012-01-11       Impact factor: 17.956

6.  Direct in vivo measurement of human cerebral GABA concentration using MEGA-editing at 7 Tesla.

Authors:  Melissa Terpstra; Kamil Ugurbil; Rolf Gruetter
Journal:  Magn Reson Med       Date:  2002-05       Impact factor: 4.668

7.  Cancer-associated IDH1 mutations produce 2-hydroxyglutarate.

Authors:  Lenny Dang; David W White; Stefan Gross; Bryson D Bennett; Mark A Bittinger; Edward M Driggers; Valeria R Fantin; Hyun Gyung Jang; Shengfang Jin; Marie C Keenan; Kevin M Marks; Robert M Prins; Patrick S Ward; Katharine E Yen; Linda M Liau; Joshua D Rabinowitz; Lewis C Cantley; Craig B Thompson; Matthew G Vander Heiden; Shinsan M Su
Journal:  Nature       Date:  2009-12-10       Impact factor: 49.962

8.  An integrated genomic analysis of human glioblastoma multiforme.

Authors:  D Williams Parsons; Siân Jones; Xiaosong Zhang; Jimmy Cheng-Ho Lin; Rebecca J Leary; Philipp Angenendt; Parminder Mankoo; Hannah Carter; I-Mei Siu; Gary L Gallia; Alessandro Olivi; Roger McLendon; B Ahmed Rasheed; Stephen Keir; Tatiana Nikolskaya; Yuri Nikolsky; Dana A Busam; Hanna Tekleab; Luis A Diaz; James Hartigan; Doug R Smith; Robert L Strausberg; Suely Kazue Nagahashi Marie; Sueli Mieko Oba Shinjo; Hai Yan; Gregory J Riggins; Darell D Bigner; Rachel Karchin; Nick Papadopoulos; Giovanni Parmigiani; Bert Vogelstein; Victor E Velculescu; Kenneth W Kinzler
Journal:  Science       Date:  2008-09-04       Impact factor: 47.728

9.  Cystathionine: A novel oncometabolite in human breast cancer.

Authors:  Suvajit Sen; Brain Kawahara; Sushil K Mahata; Rebecca Tsai; Alexander Yoon; Lin Hwang; Kayla Hu-Moore; Carissa Villanueva; Abdulqadir Vajihuddin; Pooja Parameshwar; Michelle You; Divya Lakshmi Bhaskar; Omar Gomez; Kym F Faull; Robin Farias-Eisner; Gautam Chaudhuri
Journal:  Arch Biochem Biophys       Date:  2016-06-14       Impact factor: 4.013

10.  Systemic depletion of L-cyst(e)ine with cyst(e)inase increases reactive oxygen species and suppresses tumor growth.

Authors:  Shira L Cramer; Achinto Saha; Jinyun Liu; Surendar Tadi; Stefano Tiziani; Wupeng Yan; Kendra Triplett; Candice Lamb; Susan E Alters; Scott Rowlinson; Yan Jessie Zhang; Michael J Keating; Peng Huang; John DiGiovanni; George Georgiou; Everett Stone
Journal:  Nat Med       Date:  2016-11-21       Impact factor: 53.440

View more
  21 in total

1.  In vivo 1 H MRS detection of cystathionine in human brain tumors.

Authors:  Francesca Branzoli; Dinesh K Deelchand; Marc Sanson; Stéphane Lehéricy; Małgorzata Marjańska
Journal:  Magn Reson Med       Date:  2019-05-26       Impact factor: 4.668

Review 2.  Determinants of nutrient limitation in cancer.

Authors:  Mark R Sullivan; Matthew G Vander Heiden
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-06-04       Impact factor: 8.250

3.  Is there a prominent role for MR spectroscopy in the clinical management of brain tumors?

Authors:  Olivier Keunen; Simone P Niclou
Journal:  Neuro Oncol       Date:  2020-07-07       Impact factor: 12.300

4.  The role of 2-hydroxyglutarate magnetic resonance spectroscopy for the determination of isocitrate dehydrogenase status in lower grade gliomas versus glioblastoma: a systematic review and meta-analysis of diagnostic test accuracy.

Authors:  Chinmay Sharma; Muhammad Ibrahim; Abhishta Bhandari; Matthew Riggs; Rhondda Jones; Arian Lasocki
Journal:  Neuroradiology       Date:  2021-04-03       Impact factor: 2.804

5.  MRSCloud: A cloud-based MRS tool for basis set simulation.

Authors:  Steve C N Hui; Muhammad G Saleh; Helge J Zöllner; Georg Oeltzschner; Hongli Fan; Yue Li; Yulu Song; Hangyi Jiang; Jamie Near; Hanzhang Lu; Susumu Mori; Richard A E Edden
Journal:  Magn Reson Med       Date:  2022-07-01       Impact factor: 3.737

6.  Spectral editing in 1 H magnetic resonance spectroscopy: Experts' consensus recommendations.

Authors:  In-Young Choi; Ovidiu C Andronesi; Peter Barker; Wolfgang Bogner; Richard A E Edden; Lana G Kaiser; Phil Lee; Małgorzata Marjańska; Melissa Terpstra; Robin A de Graaf
Journal:  NMR Biomed       Date:  2020-09-18       Impact factor: 4.044

Review 7.  MRI biomarkers in neuro-oncology.

Authors:  Marion Smits
Journal:  Nat Rev Neurol       Date:  2021-06-20       Impact factor: 42.937

Review 8.  Hyperpolarized MRI, functional MRI, MR spectroscopy and CEST to provide metabolic information in vivo.

Authors:  Peter C M van Zijl; Kevin Brindle; Hanzhang Lu; Peter B Barker; Richard Edden; Nirbhay Yadav; Linda Knutsson
Journal:  Curr Opin Chem Biol       Date:  2021-07-20       Impact factor: 8.972

9.  Cystathionine-γ-lyase drives antioxidant defense in cysteine-restricted IDH1-mutant astrocytomas.

Authors:  Andrés Cano-Galiano; Anais Oudin; Fred Fack; Maria-Francesca Allega; David Sumpton; Elena Martinez-Garcia; Gunnar Dittmar; Ann-Christin Hau; Alfonso De Falco; Christel Herold-Mende; Rolf Bjerkvig; Johannes Meiser; Saverio Tardito; Simone P Niclou
Journal:  Neurooncol Adv       Date:  2021-04-09

Review 10.  Magnetic resonance spectroscopy of isocitrate dehydrogenase mutated gliomas: current knowledge on the neurochemical profile.

Authors:  Francesca Branzoli; Małgorzata Marjańska
Journal:  Curr Opin Neurol       Date:  2020-08       Impact factor: 6.283

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.